Clinical trials: TSH
Goiter, Nodular
LISA-study : Levothyroxin in Nodular Goiter
Primary objective: To evaluate change in total volume of all nodules. Secondary objectives: To evaluate change in goiter volume after a 12-months treatment, number of nodules and echogenicity of nodules.
- Trial name
- NCT00277589
- Testing
- Levothyroxin-Na, Levothyroxine-Na + iodide, Iodide
- Where
- Germany
- Volunteers
- 1,024 people
- Sponsor
- Sanofi
Spinocerebellar Degeneration
A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety and pharmacokinetics of KPS-0373 in SCD patients.
- Trial name
- NCT01970098
- Testing
- KPS-0373, High dose, KPS-0373, Low dose
- Where
- Japan
- Volunteers
- 374 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Graves' Disease
A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease
An open label study to evaluate the safety and efficacy of CFZ533 following 12 weeks treatment in patients with Graves' disease
- Trial name
- NCT02713256
- Testing
- CFZ533
- Where
- 3 sites in United States, Germany
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Spinocerebellar Degeneration
An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
The purpose of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients.
- Trial name
- NCT01970111
- Testing
- KPS-0373, High dose, KPS-0373, Low dose
- Where
- Japan
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Spinocerebellar Degeneration
Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD
- Trial name
- NCT00863538
- Testing
- KPS-0373
- Where
- 3 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Spinocerebellar Degeneration
A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients (Experience of clinical trials of KPS-0373)
- Trial name
- NCT01970137
- Testing
- KPS-0373, High dose, KPS-0373, Low dose
- Where
- Japan
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Spinocerebellar Degeneration
A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
The purpose of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients
- Trial name
- NCT01970124
- Testing
- KPS-0373, High dose, KPS-0373, Low dose
- Where
- Japan
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Hypothyroidism
Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit
This is a Phase 4, single-center, open-label, interventional study, wherein all enrolled subjects will be tested for Thyroid Stimulating Hormone (TSH) by using the quantitative and the qualitative Point-of-Care (POC) TSH test…
- Trial name
- NCT01921452
- Testing
- Quantitative POC TSH Kit, Qualitative POC TSH Kit, Third generation TSH Kit
- Where
- China
- Volunteers
- 283 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Graves' Disease
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body.
- Trial name
- NCT07682896
- Testing
- Experimental: YB-101
- Where
- 29 sites in United States, Australia
- Volunteers
- 232 people
- Sponsor
- Yarrow Bioscience, Inc.
SCD
A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
The purpose of this study is to evaluate the efficacy and safety of KPS-0373 compared to placebo in patients with Spinocerebellar Degeneration (SCD).
- Trial name
- NCT01384435
- Testing
- KPS-0373
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Differentiated Thyroid Cancer
rhTSH for Radioactive Iodine Remnant Ablation in Differentiated Thyroid Cancer
This is a randomized, open, parallel controlled, multi-center clinical trial; 120 subjects were randomly assigned to the test group and the control group according to 3:1.
- Trial name
- NCT04447183
- Testing
- Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH), radioactive iodine
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Graves' Disease
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants…
- Trial name
- NCT07286006
- Testing
- IMVT-1402
- Where
- 131 sites in United States, Australia and 9 more
- Volunteers
- 372 people
- Sponsor
- Immunovant Sciences GmbH
Healthy
BE of Euthyrox® Tablets (Merck Nantong Versus Merck Darmstadt Sites)
The purpose of this study is to demonstrate bioequivalence (BE) between Euthyrox® tablets manufactured at Merck Nantong (Test Euthyrox) versus the tablets manufactured at Merck Darmstadt (Reference Euthyrox).
- Trial name
- NCT05174000
- Testing
- Test Euthyrox®, Reference Euthyrox®
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism
Clinical Evaluation of NeoPlex4 Assay and NeoPlex System
The purpose of this study is to assess the agreement of clinical performance between the proposed NeoPlex 4 assay and NeoPlex System and the comparator devices in clinical use in newborn screening programs for detection of T4…
- Conditions
- Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism, Cystic Fibrosis
- Trial name
- NCT01488721
- Where
- 3 sites in United States
- Volunteers
- 7,462 people, healthy volunteers welcome
- Sponsor
- Luminex Corporation
Graves' Disease
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid…
- Trial name
- NCT07018323
- Testing
- IMVT-1402
- Where
- 163 sites in United States, Australia and 16 more
- Volunteers
- 210 people
- Sponsor
- Immunovant Sciences GmbH
Healthy
Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone
Forty-six (46) eligible, healthy subjects who provide written informed consent will be enrolled to participate in a 2 arm parallel group study to assess and compare the pharmacokinetics and safety profile of Thyrogen dosed at 0.1…
- Trial name
- NCT00137891
- Testing
- Modified Release rhTSH
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Differentiated Thyroid Cancer
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
Patients diagnosed with thyroid cancer are commonly treated with surgery to remove their thyroid gland followed by radioiodine ablation to destroy any remaining parts of the thyroid gland that may have been missed during surgery.
- Trial name
- NCT00295763
- Testing
- Thyrogen (thyrotropin alfa for injection)
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 61 people
- Sponsor
- Genzyme, a Sanofi Company
Subclinical Hypothyroidism
Dietary Intervention With Únicla Dairy Products (DANTIAN)
Dietary intervention with Únicla dairy products, naturally enriched with selenium and omega-3 fatty acids, may improve thyroid-stimulating hormone (TSH) levels in women with subclinical hypothyroidism
- Trial name
- DANTIAN (NCT05019118)
- Testing
- Experimental milk, Experimental yogur, Experimental fresh cheese
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Cooperativas Lacteas Unidas
Differentiated Thyroid Cancer
rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)
This study was conducted in patients with differentiated thyroid cancer who had undergone total/near-total thyroidectomy. After surgery patients were randomized to one of two methods of performing thyroid remnant ablation.
- Trial name
- NCT04964284
- Testing
- rhTSH, Radioiodine (131I)
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd